arrow
P

Paul M. Ridker

Brigham and Women's Hospital
H指数:226
被引数:23.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease

司美格鲁肽在糖尿病合并慢性肾脏病中的肾脏和生存获益

JACC
IF0
2026-06-020
OAAI
A quantitative method to estimate free interleukin-6 among patients treated with the interleukin-6 ligand inhibitor ziltivekimab: comparison to C-reactive protein with implications for the ZEUS, HERMES, and ARTEMIS cardiovascular outcomes trials

一种用于估算接受白细胞介素-6配体抑制剂ziltivekimab治疗的患者中游离白细胞介素-6的定量方法:与C反应蛋白的比较及其对ZEUS、HERMES和ARTEMIS心血管结局试验的启示

2026-05-280
PRE
Anti-inflammatory effects of oral NLRP3 inhibition with ruvonoflast among individuals at elevated cardiovascular risk

口服NLRP3抑制剂ruvonoflast在心血管风险升高人群中的抗炎作用

JACC
IF0
2026-05-260
OAAI
Polygenic Risk Based Detection and Treatment of Subclinical Coronary Atherosclerosis in the PROACT Clinical Trials

基于多基因风险对亚临床冠状动脉粥样硬化的检测与治疗:PROACT临床研究

JACC
IF0
2026-02-180
PRE
Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials

心衰伴射血分数保留或轻度降低患者中的Ziltivekimab:ATHENA和HERMES试验的背景与设计

2026-01-010
OA
C-reactive protein and cardiovascular risk in the general population

C-反应蛋白和普通人群中的心血管风险

2025-12-011
PRE
A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk

一种用于预测全谱心血管风险范围内新发心力衰竭的多基因风险评分

JACC
IF0
2025-08-270
PRE
Effect of intravenous methotrexate carried by lipid nanoemulsion in patients with anterior ST-elevation myocardial infarction

脂质纳米乳载药静脉注射甲氨蝶呤对前壁ST段抬高型心肌梗死患者的影响

2025-08-130
PREAI